Open Accessibility Menu

Moles

Mole Assessment & Removal in Washington DC

Moles are clusters of pigmented cells that often appear as small, dark brown spots or can come in a range of colors or sizes and can develop virtually anywhere on your body.

Most moles are harmless, but in rare cases, moles may become cancerous. Monitoring moles and other pigmented patches is an important step in detecting skin cancer, especially malignant melanoma.

Moles generally can be removed during an in-office procedure.

Clinical Trials

  • Study for patients with moderate to severe Chronic Plaque Psoriasis - A Phase 3, Randomized, double-blind and open label study to test the safety and efficacy of Certolizumab Pegol in subjects with moderate to severe Chronic Plaque Psoriasis
    The study will test the safety and effectiveness of Certolizumab Pegol vs placebo in patients with Chronic Plaque Psoriasis. An Open Label study will follow the placebo phase.
  • Prurigo Nodularis (Chronic Prurigo)
    This study is a 12-month, observational, non-interventional study assessing biomarkers, clinical outcomes, and treatment-responsiveness in patients with prurigo nodularis (PN).Patients must be 18 years or older with a confirmed diagnosis of PN (with predominantly nodular disease) by the PI. They must be able to read and understand the consent form and outcomes questionnaires and willing and able to sign the consent form. A separate consent form will be used for genomics testing, which is encouraged for all study participants but not required. Lastly, patients must be willing to participate in the following study-related activities:1) Completion of outcome questionnaires2) Actigraphy data collection3) Biomarker collection by blood draws at each monthly study visit4) Skin biopsy collection5) Medical photography (8-24 photos taken each visit)
  • Photodynamic Therapy for Papulopustular Rosacea
    Dermatology at The GW Medical Faculty Associates is conducting an experimental research study to examine the efficacy of 5-aminolevulinic acid photodynamic therapy (5-ALA PDT) in treating rosacea. The purpose of this study is to evaluate if using 5-ALA PDT improves rosacea symptoms. We are seeking individuals with rosacea between the ages of 18 and 79 to volunteer to participate in this study. This study will take a total of six months (six total visits to the MFA). Prior to each visit, you will be examined and fill out a questionnaire. Participation in the study will be of no direct cost to you. If you are interested in participating in this research study, please contact Dermatology atThe GW Medical Faculty Associates.
  • A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    The goal of this study is to evaluate the safety and efficacy of lebrikizumab compared with placebo in patients with moderate-to-severe atopic dermatitis (AD). The dose-response of lebrikizumab in patients will also be measured. Patients with moderate-to-severe AD will be enrolled into this 32-week study. Patients will be seen every 2 weeks, will receive all study drug injections in the clinic, and be evaluated for safety and efficacy through Week 16. A safety follow-up visit will occur at Week 24 and a follow-up phone call will occur at Week 32.
  • A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Moderate to Severe Atopic Dermatitis
    The goal of this study is to evaluate the efficacy and safety of baricitinib 1-mg daily and 2-mg daily in comparison to placebo in adult patients with moderate to severe atopic dermatitis. The study is divided into 3 periods: a 5-week Screening Period, a 104-week Double-Blinded Treatment Period, and a 4-week Post-Treatment Follow-Up Period.
  • A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Active Cutaneous Lupus Erythematosus.
    The goal of this study is to evaluate the efficacy of BIIB059 in reducing disease activity in subjects with active cutaneous lupus erythematosus (CLE). The subject screening period will last up to 4 weeks. This will be followed by a treatment period of 16 weeks, with subjects randomized to 1 of 4 possible arms, all which will receive monthly treatments given in the office. Two groups will receive BIIB059 and two groups will receive the placebo. The following safety follow-up period will consist of 12 weeks of monthly visits.
  • Topical collagen powder as a wound healing adjuvant for acute full-thickness punch biopsy-induced human wounds: a pilot study
    The GW Medical Faculty Associates Department of Dermatology is conducting an experimental research study to assess collagen powder in treating acute wounds. The purpose of this study is to see if Nuvagen‚Ñ¢ (collagen powder) is effective in treating skin punch biopsy wounds. We are seeking healthy individuals between ages 18-75 to volunteer to participate in this study. The study will take a total of 12 weeks, including 6 total visits to the dermatology clinic. You will receive 1 punch biopsy on each thigh at the 1st and 4th visits. You will also be asked questions about your medical history, answer surveys, and have photographs taken. Participation in the study will be of no direct cost to you.
Related Blog Articles
  • Sunburn Vs. Windburn: What's the Difference Between These Two Winter Skin Concerns?

    When it comes to skin woes, most of us have probably suffered from sunburn or windburn — or both — at one time or another. In fact, on a ski trip last year that my parents promised would be fun, ...

    Read Full Article
  • The Best Skin Care Routine for Rosacea, According to Dermatologists

    This common skin condition often goes more than skin deep and can have devastating effects on self-confidence and self-esteem. A rosacea-proof skin care routine can help put the brakes on the ...

    Read Full Article